Response to: Correspondence on "Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis" by Sparks et al.
Zachary S WallaceJeffrey A SparksPhilip C RobinsonPedro M MachadoJinoos YazdanyPublished in: Annals of the rheumatic diseases (2021)